Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolperisone plus NSAID for acute non-specific low back pain
2021-006042-13Phase 3Completed
- Sponsor
- Meditop Pharmaceutical
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in lumbodynia (LBP) comparing Tolperisone (Miderizone) + standardized NSAID with Placebo + standardized NSAID (2 arms). Primary endpoint: Change in pain VAS score from Baseline to Day 5. Started Jan 2022; status: completed.
02
Drugs
tolperisone
03
Conditions
lumbodynia (LBP)
Beyond the preview
Go deeper on 2021-006042-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006042-13.